Growth Factors in Thoracic Cancers

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Cellular Biochemistry".

Deadline for manuscript submissions: closed (31 August 2022) | Viewed by 3700

Special Issue Editors


E-Mail Website
Guest Editor
Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria
Interests: growth factors in cancer; malignant pleural mesothelioma; fibroblast growth factor; activin; optogenetics in cancer research

E-Mail Website
Guest Editor
Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Centre Vienna, Medical University Vienna, A-1090 Vienna, Austria
Interests: surgical oncology; multimodality treatment approaches; minimal invasive surgery; interventional bronchoscopy; experimental targeted therapy in mesothelioma and lung cancer; genomic profiling of mesothelioma and lung cancer; biomarkers
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Translational Thoracic Oncology Lab, Department of Thoracic Surgery, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria
2. Center for Cancer Research, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria
Interests: malignant pleural mesothelioma; small cell lung cancer; fibroblast growth factors in cancer; EMT and cell migration; YB-1; microRNAs in cancer

Special Issue Information

Dear Colleagues,

Growth factors are indispensable signaling molecules for cell communication. They control not only cell growth but numerous additional cell behaviors including differentiation, survival, and migration. Deregulated expression of growth factors is found in many types of cancers and contributes to tumor growth, neoangiogenesis, immune evasion, and metastasis. On the one hand, specific growth factors have become important therapeutic targets and relevant biomarkers in clinical applications. On the other hand, new roles of already well-known growth factors or of hitherto less explored growth factors are constantly being discovered. This Special Issue welcomes work on all aspects of growth factors in thoracic cancers including lung cancer, esophageal cancer, malignant pleural mesothelioma, and thymic malignancies. In all of these cancers, growth factors fundamentally contribute to tumorigenesis not only via cell-autonomous functions but also via the tumor microenvironment. Nevertheless, many aspects of growth factor biology in these cancers and of their application for the benefit of patients still remain to be elucidated. We invite original research papers in the thoracic cancer field addressing growth factor functions, regulation of their expression and secretion, advances in analysis methods, and novel uses as biomarkers and/or therapy targets. Expert reviews discussing any of the above topics are also highly welcome.

Prof. Dr. Michael Grusch
Prof. Dr. Mir Alireza Hoda
Dr. Karin Schelch
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • growth factor
  • signal transduction
  • biomarker
  • therapy target
  • lung cancer
  • esophageal cancer
  • malignant pleural mesothelioma
  • thymic malignancy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 1597 KiB  
Article
Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients
by Anna Buder, Ellen Heitzer, Julie Waldispühl-Geigl, Sabrina Weber, Tina Moser, Maximilian J. Hochmair, Klaus Hackner, Peter Errhalt, Ulrike Setinek and Martin Filipits
Biomolecules 2021, 11(5), 618; https://doi.org/10.3390/biom11050618 - 21 Apr 2021
Cited by 12 | Viewed by 2980
Abstract
Background: To assess the clinical relevance of genome-wide somatic copy-number alterations (SCNAs) in plasma circulating tumor DNA (ctDNA) from advanced epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma patients. Methods: We included 43 patients with advanced EGFR T790M-positive lung adenocarcinoma who were [...] Read more.
Background: To assess the clinical relevance of genome-wide somatic copy-number alterations (SCNAs) in plasma circulating tumor DNA (ctDNA) from advanced epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma patients. Methods: We included 43 patients with advanced EGFR T790M-positive lung adenocarcinoma who were treated with osimertinib after progression under previous EGFR-TKI therapy. We performed genomic profiling of ctDNA in plasma samples from each patient obtained pre-osimertinib and after patients developed resistance to osimertinib. SCNAs were detected by shallow whole-genome plasma sequencing and EGFR mutations were assessed by droplet digital PCR. Results: SCNAs in resistance-related genes (rrSCNAs) were detected in 10 out of 31 (32%) evaluable patients before start of osimertinib. The presence of rrSCNAs in plasma before the initiation of osimertinib therapy was associated with a lower response rate to osimertinib (50% versus 81%, p = 0.08) and was an independent predictor for shorter progression-free survival (adjusted HR 3.33, 95% CI 1.37–8.10, p = 0.008) and overall survival (adjusted HR 2.54, 95% CI 1.09–5.92, p = 0.03). Conclusions: Genomic profiling of plasma ctDNA is clinically relevant and affects the efficacy and clinical outcome of osimertinib. Our approach enables the comprehensive assessment of SCNAs in plasma samples of lung adenocarcinoma patients and may help to guide genotype-specific therapeutic strategies in the future. Full article
(This article belongs to the Special Issue Growth Factors in Thoracic Cancers)
Show Figures

Figure 1

Back to TopTop